No Data
No Data
Humanwell Healthcare's Unit Gets FDA's Nod to Market Two Drugs
The US Food and Drug Administration approved the application of Humanwell Healthcare Group's (SHA:600079) unit, Epic Pharma, for two drugs, the company said in its filing on the Shanghai Stock Exchang
Humanwell Healthcare's Unit Gets Nod to Strengthen Oxycodone Hydrochloride Tablets' Dosage
Chinese drug regulator National Medical Products Administration approved the application of Yichang Humanwell Pharmaceutical, a unit of Humanwell Healthcare Group (SHA:600079), to increase the strengt
Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Shares Lagging The Market But So Is The Business
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 32x, you may consider Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) as a highly attractive investment w
Could The Market Be Wrong About Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) Given Its Attractive Financial Prospects?
Humanwell Healthcare (Group)Ltd (SHSE:600079) has had a rough three months with its share price down 24%. However, stock prices are usually driven by a company's financial performance over the long
China Approves Sale of Humanwell Healthcare Unit's Prostate Cancer Treatment
China's medical products administrator granted Humanwell Healthcare Group (SHA:600079) unit Yichang Renfu Pharmaceutical a drug registration certificate for its enzalutamide soft capsules, according t
Renfu Pharmaceutical (600079.SH): Enzalutamide softgels obtained drug registration certificate
Gelonghui, March 5 | Renfu Pharmaceutical (600079.SH) announced that Yichang Renfu recently received the “Drug Registration Certificate” for enzalumide softgels approved and issued by the State Drug Administration. Enzalutamide is an androgen receptor inhibitor suitable for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (NM-CPRC) with a high risk of metastatic metastasis; it is also suitable for the treatment of adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or have mild symptoms after failure of androgen deprivation therapy (ADT) and have not received chemotherapy.
No Data